文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

双氢青蒿素/哌喹用于疟疾间歇性预防治疗对感染HIV孕妇多替拉韦暴露的影响

Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

在马拉维开展开放标签、非随机、固定序列药代动力学研究,12名妊娠中晚期感染HIV孕妇在双氢青蒿素/哌喹3天疗程前后各测24小时多替拉韦浓度。联用后多替拉韦AUC0-24和Cmax分别升高30%(GMR 1.30;90% CI 1.11-1.52)和31%(GMR 1.31;90% CI 1.13-1.51),C24升高42%(GMR 1.42;90% CI 1.09-1.85),耐受良好,未观察到严重不良事件。作者认为双氢青蒿素/哌喹可与基于多替拉韦的抗逆转录病毒治疗联用。

要点

  • 妊娠中晚期感染HIV孕妇联用双氢青蒿素/哌喹后多替拉韦AUC0-24升高30%(GMR 1.30;90% CI 1.11-1.52)。
  • 多替拉韦Cmax升高31%(GMR 1.31;90% CI 1.13-1.51),C24升高42%(GMR 1.42;90% CI 1.09-1.85)。
  • 联合治疗耐受良好,未观察到严重不良事件。

核心结论

  • 作者认为双氢青蒿素/哌喹可与基于多替拉韦的抗逆转录病毒治疗在孕妇中联用,多替拉韦暴露的适度增加与既往发表的药代动力学参数值相似,可确保其疗效,且在这项小样本研究中未观察到有临床意义的不良事件。

研究设计与样本

  • 在马拉维感染HIV人群中开展开放标签、非随机、固定序列药代动力学研究,纳入12名妊娠中晚期孕妇,在推荐的双氢青蒿素/哌喹3天治疗剂量前后各进行24小时多替拉韦浓度测定,采用非房室分析,生成几何均值比(GMR)和90% CI比较两个治疗期的多替拉韦药代动力学参数。

主要发现

  • 联用双氢青蒿素/哌喹和多替拉韦使多替拉韦总暴露(AUC0-24)升高30%(GMR 1.30;90% CI 1.11-1.52),Cmax升高31%(GMR 1.31;90% CI 1.13-1.51),谷浓度(C24)升高42%(GMR 1.42;90% CI 1.09-1.85)。
  • 联合治疗耐受良好,未观察到严重不良事件。

临床怎么用

  • 作者认为双氢青蒿素/哌喹可与基于多替拉韦的抗逆转录病毒治疗在孕妇中联用。

局限性

  • 原文在结论中自述为小样本研究(small study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In sub-Saharan Africa, the burdens of malaria and HIV infections overlap. In settings with moderate-to-high malaria transmission intensity, pregnant women living with HIV (PLWH) require both ART and malaria intermittent preventive treatment (IPTp). Dihydroartemisinin/piperaquine has been identified as a promising alternative to sulfadoxine/pyrimethamine for IPTp. However, another antimalarial drug, artesunate/amodiaquine, similar to dihydroartemisinin/piperaquine, was previously shown to reduce dolutegravir exposure in non-pregnant adults. OBJECTIVES: To investigate the effect of dihydroartemisinin/piperaquine on dolutegravir plasma exposure in pregnant women on dolutegravir-based ART. METHODS: We conducted an open-label, non-randomized, fixed-sequence, pharmacokinetic study in PLWH in Malawi. Dolutegravir concentrations were measured over a 24 h period, before and after the recommended 3 day treatment dose of dihydroartemisinin/piperaquine in 12 pregnant women in their second or third trimester. Non-compartmental analysis was performed, and geometric mean ratios (GMRs) and 90% CIs were generated to compare dolutegravir pharmacokinetic parameters between the two treatment periods. RESULTS: Co-administration of dihydroartemisinin/piperaquine and dolutegravir increased dolutegravir's overall exposure (AUC0-24) and Cmax by 30% (GMR 1.30; 90% CI 1.11-1.52) and 31% (GMR 1.31; 90% CI 1.13-1.51), respectively. The dolutegravir trough (C24) concentration increased by 42% (GMR 1.42; 90% CI 1.09-1.85). The combined treatments were well tolerated with no serious adverse events observed. CONCLUSIONS: Dihydroartemisinin/piperaquine may be administered with dolutegravir-based ART in pregnant women as the modest increase in dolutegravir exposure, similar to pharmacokinetic parameter values published previously, ensures its efficacy without any clinically significant adverse events observed in this small study.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Banda CG, Nkosi D, Allen E, et al. Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV. J Antimicrob Chemother. 2022. PMID: 35288747. doi:10.1093/jac/dkac081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。